The world’s biggest medical cannabis markets have embraced cannabis telemedicine as their primary access method, but it is also their Achilles Heel.
Poland’s case, in which a regulatory intervention reduced dispensing by half within a few weeks before the market staged a complete recovery during the subsequent 12 months, is one of the best data-rich examples available on what happens to telemedicine when access is interrupted.
This book is required reading for investors, operators and policymakers who are watching Germany, Australia and the UK as they navigate through similar tensions.
Telemedicine Transformed Cannabis Access — Then Became a Target
In Europe, the story of growth in medical cannabis over the past 5 years has been largely a story about telemedicine. Connecting patients to willing prescribers through digital platforms has removed the biggest barrier for access, which was geography. Rural patients without sympathetic doctors could consult online. The friction of booking, travelling, and sitting in a waiting room was replaced by online questionnaires and video calls — sometimes lasting only minutes.
Telemedicine platforms in Poland helped increase dispensing volume from 1 ton per year by 2021, up to 5 tons at the end of 2023. Telemedicine platforms in Germany have led to a significant increase in the import of medical cannabis after April 2024 when cannabis was reclassified outside its narcotics laws. The authorities suspended all new import licenses temporarily. The model was used in Australia to fuel one of the most rapid patient ramps ever seen.
Regulators and the media in each market began to question whether cannabis was being accessed recreationally through telemedicine under the guise of medical use. The reports of little clinical oversight, platform marketing that was aggressive, and prescriptions given without consultation sparked a reaction in Poland.
Understanding the dynamics of cannabis telemedicine — the access it enables, the vulnerabilities it creates, and the market impact when it is restricted — has become one of the most commercially significant questions in the global cannabis industry.
Poland: The Natural Experiment
Poland’s market for medical cannabis provided a unique experience: an entire cycle, backed by data, of growth fueled by telemedicine and regulatory shocks, followed quickly with a market recovery.
It is clear what the timeline will be. Polish authorities began requiring patients to undergo in-person consultations when they requested medical cannabis prescriptions. The telemedicine model, which was driving the rapid market expansion, will be effectively ended by the end of November 2024. The stated rationale centred on concerns about prescription abuse and insufficient clinical oversight — criticisms that echoed debates in Germany and Australia.
Market impact was severe and immediate. Monthly prescriptions collapsed from approximately 68,000 in October 2024 to around 28,000 by December — a decline of more than half in just two months. Dispensing volumes followed a similar trajectory.
The crash itself isn’t what makes Poland unique. The next step is the most important.
It’s Professionalisation and Not Regression that will bring about the recovery.
The narrative that might have been expected — a market permanently diminished by regulatory intervention — did not materialise. Poland’s medical marijuana sector, however, has adapted and restructured to reach its volume pre-ban levels in just 12 months.
It took a while for the recovery to occur. In 2025, the first quarter remained depressed. Volumes increased through mid-year, but by October 2025 monthly dispensing exceeded the peak before the ban. The December 2025 high was a record.
Full-year 2025 figures tell the story clearly: Polish pharmacies dispensed approximately 5,450 kilograms of dried cannabis flower, a 12% increase over 2024 — a year that included the pre-ban peak months.
The recovery has been driven more by structural changes than it was a return of the status quo. The loosely-regulated telemedicine operation that drove earlier growth was largely replaced with more structured clinics. Some operators sent prescribers into temporary locations within smaller cities to recreate the geographical access provided by telemedicine. Some operators established permanent clinics that had more stringent consultation procedures. As a result of pressure on the market, it became professionalised.
The pattern is important for markets that are subject to similar regulations. The Poland data suggests that telemedicine restrictions do not necessarily destroy demand — but they do reshape supply chains, change the economics of patient acquisition, and impose a significant, if temporary, disruption.
What is the price story hidden in volume recovery?
The volume recovery however is only part of the picture. Poland has experienced a significant shift in its pricing structure that is not reflected by the headline figures. This change will have a profound impact on operators and investors.
Full-year 2025 revenue fell to approximately PLN 253 million (roughly €60 million) — a decline of around 19% from 2024’s peak. The average price of a gram decreased by approximately 28%, going from about 65 PLN a gram to around 47 PLN.
The market moves a lot more products for less money. The operators who have recovered their patient base after the ban on telemedicine and survived it are now in competition with a market that has seen margins significantly compressed. Volume recovery is real but revenue growth hasn’t followed.
This dynamic — rising volumes, falling revenues — is a pattern that investors in cannabis markets globally should watch carefully. This suggests that the market structure after telemedicine may be fundamentally distinct from that which preceded it. It could have implications for the company’s valuation, entry into the market, and strategic strategy.
This document contains the complete pricing dynamics including the monthly granularity over 84-months of data. Poland Medical Cannabis Market Review, 2026.
Germany is following Poland’s Playbook: Why this matters now
Poland’s case would make a powerful study if it were studied in isolation. The fact that Europe’s most important medical cannabis market is heading in the same direction makes this urgent.
On October 20, 2025, German Federal Cabinet passed amendments to Medical Cannabis Act that ban remote prescribing as well as mail-order distribution of medical marijuana. The proposed law would mandate an initial consultation in-person, and allow follow-up prescriptions via telemedicine if there has already been a face-to-face visit.
The parallels with Poland’s 2024 intervention are striking: the same concerns about telemedicine-driven overprescribing, the same political framing around patient safety, and the same industry warnings about reduced access — particularly for patients in rural areas.
Germany is in a situation with even more commercial risks. The market is estimated to be worth around €670 million, with imports surging through 2025 to the point where authorities suspended new import licences. Industry estimates suggest that only around 10-13% of total cannabis demand in Germany is currently served through medical channels, indicating significant room for continued growth — if the regulatory environment allows it.
This bill should be passed in the first quarter of 2026. Depending on its final form, the impact on Germany’s medical cannabis supply chain — from telemedicine platforms to pharmacies to importers — could be substantial.
Australia is also facing increasing pressure over telemedicine and prescribing. Political scrutiny will increase through 2025-2026.
For operators and investors in these markets, Poland’s granular monthly data — showing the precise scale and duration of disruption, the shape of recovery, and the structural changes that followed — represents the closest available evidence base for modelling their own risk scenarios.
Learn from the data: What it says about the industry
Poland’s dataset of 84 months, from January 2019 until December 2025 is a good example that could be used in any country where cannabis telemedicine regulations are being pressed.
The demand for the product has survived. This ban on telemedicine did not remove the patient’s demand. This ban displaced the demand temporarily, and changed how that was satisfied. It seems that, in markets where there is a genuine need for access to healthcare services, the regulatory restrictions are more likely to slow down growth than reverse it.
The recovery process takes time. Full volume recovery took around 12 months. Market modelling should consider a disruption of several quarters, and not just a short blip.
Professionalisation is a mechanism for adaptation. In Poland, the post-ban structure is characterized by higher standards of clinical care and stronger patient-prescriber relations than in the model from telemedicine’s era. Markets that proactively professionalise their telemedicine offerings may be able to mitigate — or avoid — the kind of regulatory intervention Poland experienced.
A structural result of the price compression. The shift from a telemedicine-dominated model to a clinic-based model appears to have coincided with significant price competition. Operators must model not just the volume of recovery, but also the impact on revenue from post-restriction pricing dynamics.
The importance of data cannot be overstated. Poland is the only European major market that has granular, monthly government data documenting the entire telemedicine recovery cycle. This dataset makes it difficult for boards, regulatory affairs teams, and investors to build scenarios around Germany or Australia.
Download the complete dataset
It is important to note that the word “you” means “you”. Poland Medical Cannabis Market Review, 2026 is a two-part package covering the complete market through full-year 2025, with three-scenario forecasts for 2026–2027:
- Written report (PDF): The report includes market size, growth trends, the impact of the ban on telemedicine, analysis of sales revenues, pricing, and implications for strategic planning. This report is intended for investors and board members.
- Interactive Excel workbook: 10 tabs, hundreds of live formulas, 84 months of data (January 2019 – December 2025) across 10+ metrics per month. Every calculated value is a live formula traceable to government source data — not a static spreadsheet.
Available as a standalone report and data package (£399) or with a two-hour market intelligence briefing from a senior Prohibition Partners analyst (£1,099).
View the report →